An Acosta Group study finds that 76% of those who discontinued GLP-1s are eating the same amount or less and many report ...

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc. (NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ...

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

FuturHealth, a leader in personalized weight-loss solutions, today announced the appointment of Keith Koch as Executive Vice President of Growth Product & Experience Design. Koch, a veteran in digital ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...

Intuitive Surgical has maintained an uptrend since late 2022 with price correcting to 200-DMA a few times and again ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...